Jazz Pharmaceuticals PLC (JAZZ)

NASDAQ
135.45
+2.16(+1.62%)
After Hours
133.45
-2.00(-1.48%)
- Real-time Data
  • Volume:
    511,241
  • Day's Range:
    133.56 - 136.37
  • 52 wk Range:
    117.64 - 169.98

JAZZ Overview

Prev. Close
133.29
Day's Range
133.56-136.37
Revenue
3.3B
Open
134.79
52 wk Range
117.64-169.98
EPS
-0.84
Volume
511,241
Market Cap
8.49B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
524,999
P/E Ratio
-187.10
Beta
0.691
1-Year Change
4.22%
Shares Outstanding
62,680,737
Next Earnings Date
Nov 08, 2022
What is your sentiment on Jazz Pharma?
or
Market is currently closed. Voting is open during market hours.

Jazz Pharmaceuticals PLC News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Jazz Pharmaceuticals PLC Analysis

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals PLC Company Profile

Employees
3200

Jazz Pharmaceuticals plc is a biopharmaceutical company. The Company is engaged in developing medicines for people with serious diseases. The Company’s products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, which develops for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy aged seven years of age and older; Xyrem (sodium oxybate) oral solution, which develops for the treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy; Epidiolex (cannabidiol) oral solution, which develops for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex in patients one year of age or older; Sunosi (solriamfetol); Sativex (nabiximols) oral solution; Zepzelca (lurbinectedin); Rylaze (recombinant Erwinia asparaginase); Vyxeos (daunorubicin and cytarabine) liposome for injection; and Defitelio (defibrotide sodium).

Read More

Analyst Price Target

Average198.58 (+46.61% Upside)
High240
Low170
Price135.45
No. of Analysts19
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
  • FDA Approves Component of Treatment Regimen for Most Common Childhood Cancerhttps://www.fda.gov/news-events/press-announcements/fda-approves-component-treatment-regimen-most-common-childhood-cancer
    0
    • A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
      1
      • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
        0
        • Take into account the risks, page 44 of th eannual report: ""However, FDA confirmed that the clinical benefit of Zepzelca based on the results of the ATLANTIS Phase 3 clinical trial evaluating Zepzelca in combination with doxorubicin for relapsed SCLC did not provide sufficient verification and we and PharmaMar will therefore need to conduct one or more additional clinical trials of Zepzelca to confirm its clinical benefit. Our failure to do so could result in the withdrawal of approval of Zepzelca, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any event, if we are unable to comply with our post-marketing obligations imposed as part of the marketing approvals in the U.S., the EU, or other European countries, our approval may be varied, suspended or revoked, product supply may be delayed and our sales of and revenues from our products could be materially adversely affected. ""
          0
          • PharmaMar's antiviral is 100 times more effective against Covid-19 than other treatments, reducing its viral load by almost 100%
            1
            • "The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
              2
              • "The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
                1
                • on so ii would need samples plenty and ill make my rounds
                  0
              • I see it as a very good stock and see very good income statements but don't know the company.. any downsides about it ?
                4
                • Buying now
                  0